These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 29845291)

  • 1. Concomitant presence of JAK2V617F mutation and BCR‑ABL translocation in two patients: A new entity or a variant of myeloproliferative neoplasms (Case report).
    Mousinho F; Azevedo AP; Mendes T; Santos PSE; Cerqueira R; Matos S; Santos S; Ramos S; Viana JF; Lima F
    Mol Med Rep; 2018 Jul; 18(1):1001-1006. PubMed ID: 29845291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unique Case of Myeloproliferative Neoplasm with Two Rare Clonal Abnormalities: Rare JAK2 Exon 12 Mutation and Rare e14a3 (b3a3) BCR/ABL Fusion Transcript.
    Swaminathan M; Patel KP; Huynh-Lu J; Tang G; Zuo Z; Miranda R; Verstovsek S
    Acta Haematol; 2019; 141(1):23-27. PubMed ID: 30463063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concomitant detection of BCR-ABL translocation and JAK2 V617F mutation in five patients with myeloproliferative neoplasm at diagnosis.
    Cappetta M; Pérez V; Zubillaga MN; Elizondo V; Manrique G; Prosper I; Boschi S; Bonomi R; Pomoli S; Díaz L; Martínez L; Uriarte MR
    Int J Lab Hematol; 2013 Feb; 35(1):e4-5. PubMed ID: 23062104
    [No Abstract]   [Full Text] [Related]  

  • 4. Emergence of chronic myelogenous leukemia from a background of myeloproliferative disorder: JAK2V617F as a potential risk factor for BCR-ABL translocation.
    Pingali SR; Mathiason MA; Lovrich SD; Go RS
    Clin Lymphoma Myeloma; 2009 Oct; 9(5):E25-9. PubMed ID: 19858050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential Development of JAK2V617F Mutation and BCR-ABL1 Fusion in Individual Patients With Myeloproliferative Neoplasms.
    Zhao Y; Reddi D; McCracken J; Iranzad N; Rehder C; Neff J; Wang E
    Arch Pathol Lab Med; 2022 Jun; 146(6):710-717. PubMed ID: 34506622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of pleckstrin-2 reverts lethality and vascular occlusions in JAK2V617F-positive myeloproliferative neoplasms.
    Zhao B; Mei Y; Cao L; Zhang J; Sumagin R; Yang J; Gao J; Schipma MJ; Wang Y; Thorsheim C; Zhao L; Stalker T; Stein B; Wen QJ; Crispino JD; Abrams CS; Ji P
    J Clin Invest; 2018 Jan; 128(1):125-140. PubMed ID: 29202466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms.
    Hummel JM; Kletecka MC; Sanks JK; Chiselite MD; Roulston D; Smith LB; Czuchlewski DR; Elenitoba-Johnson KS; Lim MS
    Diagn Mol Pathol; 2012 Sep; 21(3):176-83. PubMed ID: 22847163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical significance of JAK2V617F mutation for Philadelphia-negative chronic myeloproliferative neoplasms in patients with splanchnic vein thrombosis.
    Yonal I; Pinarbası B; Hindilerden F; Hancer VS; Nalcaci M; Kaymakoglu S; Diz-Kucukkaya R
    J Thromb Thrombolysis; 2012 Oct; 34(3):388-96. PubMed ID: 22569900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study.
    Chang H; Shih LY; Michelson AD; Dunn P; Frelinger AL; Wang PN; Kuo MC; Lin TL; Wu JH; Tang TC
    Acta Haematol; 2013; 130(3):181-7. PubMed ID: 23751441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Relationship between socs3 mRNA expression and jak2v617f point mutation in bcr-abl negative patients with myelo-proliferative disease].
    Wang DM; Pan L; Zhang JM; Li YH; Wang HF; Wang XQ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Jun; 16(3):479-83. PubMed ID: 18549612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Tyrosine kinase JAK2V617F mutation in human myeloproliferative disorders].
    Xu YY; Li HM; Li XJ; Yang L; Hu DM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):541-4. PubMed ID: 19549360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BCR-ABL negative myeloproliferative neoplasia: a review of involved molecular mechanisms.
    Koopmans SM; Schouten HC; van Marion AM
    Histol Histopathol; 2015 Feb; 30(2):151-61. PubMed ID: 25196073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The concomitant occurrence of JAK2V617F mutation and BCR/ABL transcript with phenotypic expression - an overlapping myeloproliferative disorder or two distinct diseases? - case report.
    Ursuleac I; Colita A; Adam T; Jardan C; Ilea A; Coriu D
    J Med Life; 2013 Mar; 6(1):34-7. PubMed ID: 23599815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Colony-Forming Cell Assay Detecting the Co-Expression of JAK2V617F and BCR-ABL1 in the Same Clone: A Case Report.
    Tirrò E; Stella S; Massimino M; Zammit V; Pennisi MS; Vitale SR; Romano C; Di Gregorio S; Puma A; Di Raimondo F; Stagno F; Manzella L
    Acta Haematol; 2019; 141(4):261-267. PubMed ID: 30965317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantification of JAK2V617F mutation load by droplet digital PCR can aid in diagnosis of myeloproliferative neoplasms.
    Zheng CF; Zhao XX; Chen XH; Liu Z; Wang WJ; Luo M; Ren Y; Wang HW
    Int J Lab Hematol; 2021 Aug; 43(4):645-650. PubMed ID: 33973741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. JAK2 and MPL mutations in myeloproliferative neoplasms.
    Koppikar P; Levine RL
    Acta Haematol; 2008; 119(4):218-25. PubMed ID: 18566540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic myeloproliferative diseases with concurrent BCR-ABL junction and JAK2V617F mutation.
    Hussein K; Bock O; Theophile K; Seegers A; Arps H; Basten O; Grips KH; Franz-Werner J; Büsche G; Kreipe H
    Leukemia; 2008 May; 22(5):1059-62. PubMed ID: 17972958
    [No Abstract]   [Full Text] [Related]  

  • 18. Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era.
    Tefferi A
    Hematology Am Soc Hematol Educ Program; 2006; ():240-5. PubMed ID: 17124067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myeloid neoplasms with concurrent BCR-ABL1 and CBFB rearrangements: A series of 10 cases of a clinically aggressive neoplasm.
    Salem A; Loghavi S; Tang G; Huh YO; Jabbour EJ; Kantarjian H; Wang W; Hu S; Luthra R; Medeiros LJ; Khoury JD
    Am J Hematol; 2017 Jun; 92(6):520-528. PubMed ID: 28253536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JAK2 V617F mutation prevalence in myeloproliferative neoplasms in Pernambuco, Brazil.
    da Silva RR; Domingues Hatzlhofer BL; Machado CG; Lima AS; de Albuquerque DM; dos Santos MN; Fertrin KY; Costa FF; Araújo Ada S; Bezerra MA
    Genet Test Mol Biomarkers; 2012 Jul; 16(7):802-5. PubMed ID: 22304488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.